Several biomarkers, including PD-L1 expression, tumor mutation burden (TMB), and microsatellite instability (MSI), have been developed to distinguish responders to immunotherapy from non-responders in NSCLC (20–25). The gene discussed is CD274; the disease is neoplasm.